Table 5.
Univariate analysis of predictive factors for overall survival in all patients (N = 213)
| n | mOS, month (95% CI) | Hazard ratio (95% CI)† | P‐value‡ | |
|---|---|---|---|---|
| Age, years | ||||
| <65 | 136 | 34.7 (24.7–44.0) | 1 | |
| ≥65 | 77 | 47.5 (33.9–NE) | 0.692 (0.472–1.014) | 0.0592 |
| Sex | ||||
| Male | 143 | 38.8 (32.3–50.1) | 1 | |
| Female | 70 | 39.6 (27.6–50.0) | 1.115 (0.770–1.616) | 0.5634 |
| Race | ||||
| White | 162 | 33.9 (27.6–42.8) | 1 | |
| Asian | 46 | NE (38.8–NE) | 0.489 (0.292–0.820) | 0.0066 |
| Black | 2 | 36.8 (33.0–40.6) | 1.327 (0.327–5.396) | 0.6922 |
| Other | 3 | 54.8 (4.1–54.8) | 0.818 (0.201–3.321) | 0.7782 |
| Body weight, kg | ||||
| ≤65 | 56 | 39.6 (25.5–52.6) | 1 | |
| >65 to ≤76 | 51 | 39.3 (22.9–NE) | 0.883 (0.531–1.470) | 0.6325 |
| >76 to ≤89 | 53 | 34.5 (24.7–54.8) | 0.868 (0.532–1.417) | 0.5720 |
| >89 | 53 | 41.6 (29.9–NE) | 0.866 (0.529–1.418) | 0.5675 |
| ECOG PS | ||||
| 0 | 136 | 50.0 (40.6–NE) | 1 | |
| ≥1 | 77 | 20.8 (11.7–31.9) | 2.484 (1.741–3.543) | <0.0001 |
| Prior nephrectomy | ||||
| Yes | 183 | 42.5 (34.5–50.3) | 1 | |
| No | 30 | 21.6 (10.5–34.1) | 2.139 (1.367–3.348) | 0.0009 |
| Number of metastatic sites | ||||
| 1 | 41 | 57.2 (50.0–NE) | 1 | |
| 2 | 57 | 54.8 (35.2–NE) | 1.366 (0.720–2.591) | 0.3401 |
| 3 | 52 | 38.8 (24.8–44.7) | 2.209 (1.203–4.058) | 0.0106 |
| ≥4 | 63 | 22.9 (11.7–32.7) | 3.538 (1.980–6.321) | <0.0001 |
| Metastatic sites (lung versus lung + others) | ||||
| Lung only | 25 | 57.2 (37.8–NE) | 1 | |
| Lung + others | 188 | 34.7 (28.9–43.2) | 2.057 (1.076–3.930) | 0.0291 |
| Time from histopathological diagnosis to treatment, years | ||||
| ≥1 | 88 | 57.2 (42.7–NE) | 1 | |
| <1 | 125 | 28.9 (17.6–39.3) | 2.270 (1.547–3.330) | <0.0001 |
| Time from metastatic diagnosis to treatment, years | ||||
| ≥1 | 20 | 40.1 (24.7–NE) | 1 | |
| <1 | 193 | 39.3 (32.6–46.1) | 1.050 (0.577–1.908) | 0.8736 |
| Sum of longest diameter for target lesion§ | ||||
| ≤Median¶ | 107 | 54.8 (44.0–NE) | 1 | |
| >Median¶ | 105 | 23.7 (14.5–33.9) | 2.624 (1.817–3.789) | <0.0001 |
| Presence of metastases (de novo) at initial diagnosis | ||||
| No | 119 | 50.3 (40.1–NE) | 1 | |
| Yes | 94 | 28.9 (19.5–37.8) | 2.019 (1.413–2.885) | 0.0001 |
| Baseline LDH†† | ||||
| ≤1.5 × ULN | 198 | 40.6 (33.9–47.5) | 1 | |
| >1.5 × ULN | 11 | 9.8 (3.7–30.4) | 3.149 (1.588–6.243) | 0.0010 |
| Baseline hemoglobin | ||||
| ≥LLN | 119 | 43.2 (38.6–57.2) | 1 | |
| <LLN | 94 | 30.4 (17.2–40.6) | 1.563 (1.097–2.227) | 0.0135 |
†1 equals reference. ‡Using Wald test. §One patient did not have measurable disease at baseline. ¶Median equals 89 mm in all patients. ††Values were missing for 4 patients. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; LLN, lower limit of normal; mOS, median overall survival; NE, not estimable; ULN, upper limit of normal.